(Q36520623)

14 August 2017

1 reference

title

Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction (English)

1 reference

14 August 2017

1 reference

3

Sotirios Tsimikas

1 reference

14 August 2017

Matthew K Ito

1

1 reference

PubMed ID

16803418

14 August 2017

Robert L Talbert

series ordinal

2

1 reference

PubMed ID

16803418

14 August 2017

language of work or name

English

0 references

publication date

1 July 2006

1 reference

14 August 2017

1 reference

14 August 2017

26

1 reference

14 August 2017

7 Pt 2

1 reference

14 August 2017

85S-97S; discussion 98S-101S; quiz 106S-108S

1 reference

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

14 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Management of hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Statin treatment after onset of sepsis in a murine model improves survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Statin use and fracture risk: study of a US veterans population

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Should treatment of sepsis include statins?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Simvastatin blunts endotoxin-induced tissue factor in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

C-reactive protein levels and outcomes after statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Statin therapy is associated with lower mortality among patients with severe heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

The Lipid Research Clinics Coronary Primary Prevention Trial: design, results, and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Pleiotropic effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Treating diastolic heart failure with statins: "phat" chance for pleiotropic benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Current concepts of the pathogenesis of the acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Pathophysiology of coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Statins induce the regression of left ventricular mass in patients with angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

Cardiac systolic and diastolic dysfunction after a cholesterol-rich diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.7PART2.85S

10.1592/PHCO.26.7PART2.85S

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16803418